Three Phase 3 Clinical Trials that Could Legalize Psychedelics
The road to psychedelic legalization has many paths. These 3 clinical trials have the best chances to legalize psychedelics for therapy
awakn
A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
Why Wednesday Will Be Biggest Day of 2022 for Psychedelic Investors
Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.
Top 5 Most Influential Psychedelic Studies
We unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.
End of content
End of content